Spravato contains the active ingredient esketamine, which is derived from ketamine, a dissociative anesthetic. While esketamine has a lower potential for abuse and dependence compared to ketamine, it still carries some risk.  For this reason, Spravato is administered under controlled conditions in a healthcare facility, and patients are closely monitored for any signs of abuse or dependence.